Alterations of the MEK/ERK, BMP, and Wnt/β-catenin pathways detected in the blood of individuals with lymphatic malformations.
Taehan KimElidia TafoyaMalcolm P ChelliahRamrada LekwuttikarnJiang LiKavita Y SarinJoyce TengPublished in: PloS one (2019)
Lymphatic malformation (LM) is a developmental anomaly of the lymphatic system that may lead to disfigurement, organ dysfunction and recurrent infection. Though several treatment modalities exist, pharmacotherapy is often associated with side effects and recurrence is common following surgical interventions. Moreover, despite the recent discovery of PIK3CA mutations in lymphatic endothelial cells of LM patients, the full spectrum of molecular pathways involved in LM pathogenesis is poorly understood. Here, we performed RNA sequencing on blood samples obtained from ten LM patients and nine healthy subjects and found 421 differentially expressed genes that stratify LM subjects from healthy controls. Using this LM gene signature, we identified novel pathway alterations in LM, such as oxidative phosphorylation, MEK/ERK, bone morphogenetic protein (BMP), and Wnt/β-catenin pathways, in addition to confirming the known alterations in cell cycle and the PI3K/AKT pathway. Furthermore, we performed computational drug repositioning analysis to predict existing therapies (e.g. sirolimus) and novel classes of drugs for LM. These findings deepen our understanding of LM pathogenesis and may facilitate non-invasive diagnosis, pathway analysis and therapeutic development.
Keyphrases
- cell proliferation
- cell cycle
- end stage renal disease
- lymph node
- endothelial cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- stem cells
- prognostic factors
- epithelial mesenchymal transition
- peritoneal dialysis
- mesenchymal stem cells
- oxidative stress
- physical activity
- gene expression
- emergency department
- protein kinase
- adverse drug